Form 4: OnKure Therapeutics CEO Nicholas Saccomano Reports Changes in Beneficial Ownership Following Merger
SEC Form 4 Filing
Following the merger of OnKure, Inc. with Reneo Pharmaceuticals, Inc., CEO Nicholas Saccomano reports changes in beneficial ownership of Class A Common Stock and derivative securities.
Summary
- Nicholas Saccomano, CEO of OnKure Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership of securities.
- The changes are related to the merger between OnKure, Inc. and Reneo Pharmaceuticals, Inc., which became effective on October 4, 2024.
- Saccomano acquired 4,556 shares of Class A Common Stock.
- He also acquired options to purchase shares of Class A Common Stock at various exercise prices and vesting schedules.
- These options include 2,359 shares at $21.20 exercisable from January 10, 2032, 1,485 shares at $13.99 exercisable from August 29, 2033, 16,898 shares at $13.99 exercisable from October 14, 2033, 8,449 shares at $13.99 exercisable from October 14, 2033 and 542,232 shares at $18.20 exercisable from October 3, 2034.
- The reported transactions reflect the assumption and conversion of OnKure stock options and restricted stock units (RSUs) by Reneo as part of the merger agreement.
Sentiment
Score: 7
Explanation: The document primarily reports factual information regarding changes in beneficial ownership following a merger. While the merger itself could be viewed positively, the document's sentiment is neutral as it focuses on reporting requirements.
Positives
- The merger's completion is a positive step for OnKure Therapeutics, Inc.
Future Outlook
The combined company will operate as OnKure Therapeutics, Inc., trading on The Nasdaq Stock Market under the symbol 'OKUR'.
Industry Context
Mergers and acquisitions are common in the pharmaceutical industry as companies seek to expand their pipelines, technologies, and market presence. This merger allows Reneo to acquire OnKure's assets and expertise, potentially leading to synergies and increased shareholder value.
Stakeholder Impact
- Shareholders of OnKure, Inc. and Reneo Pharmaceuticals, Inc. are impacted by the merger and the resulting changes in stock ownership.
- Employees of both companies may be affected by the integration of the two organizations.
Key Dates
| Date | Description |
|---|---|
| May 10, 2024 | Date of the Merger Agreement between Reneo Pharmaceuticals, Radiate Merger Sub I, and OnKure, Inc. |
| October 4, 2024 | Effective date of the merger between OnKure, Inc. and Reneo Pharmaceuticals, Inc. |
| October 8, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.